Bioaffinity Technologies, INC 8-K filings

bioAffinity Technologies plans to cut $4 million in costs at its PPLS subsidiary while boosting resources for CyPath Lung sales.

bioAffinity Technologies secures $1.4 million through a warrant inducement agreement, issuing new warrants to incentivize the exercise of existing ones.

bioAffinity Technologies received a notice from Nasdaq on February 7, 2025, stating that its common stock has not maintained the minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days.

bioAffinity Technologies' CEO, Maria Zannes, receives a salary increase to $300,000 per year, retroactive to November 1, 2024, as approved by the Compensation Committee.

bioAffinity Technologies' stockholders approved the issuance of shares upon warrant exercise and a proposal to adjourn the special meeting if needed, though the adjournment was not ultimately required.

BioAffinity Technologies reports a record year in sales for its CyPath Lung test and outlines plans for expansion into new markets and clinical trials in 2025.

bioAffinity Technologies reported a significant increase in revenue for Q3 2024, driven by expanded sales of its CyPath Lung test and a recent acquisition.

bioAffinity Technologies has successfully priced a $2.66 million offering, combining a registered direct offering of common stock with a concurrent private placement of warrants.

bioAffinity Technologies has appointed J. Michael Edwards as its Chief Financial Officer, effective November 5, 2024, marking his return to the company after serving as interim CFO.

bioAffinity Technologies' CyPath Lung test, a noninvasive diagnostic for early-stage lung cancer, has been added to the U.S. Federal Supply Schedule, providing streamlined access for Veterans Health Administration and Military Health System patients.

bioAffinity Technologies' stockholders approved the issuance of shares upon warrant exercises and a proposal to adjourn the special meeting if needed, though the adjournment was not ultimately required.

BioAffinity Technologies' CFO, Michael Dougherty, is resigning to pursue another opportunity, and former CFO, Michael Edwards, will return as interim CFO.

bioAffinity Technologies raises $1.75 million through a combination of warrant exercises and a direct offering, aiming to bolster working capital.

bioAffinity Technologies announced a 217% increase in second-quarter sales of its CyPath Lung test compared to the first quarter of 2024 and raised its full-year sales forecast by 85%.

bioAffinity Technologies' stockholders approved a new incentive compensation plan and an increase in authorized common stock shares at the 2024 Annual Meeting.

BioAffinity Technologies announced record first-quarter revenue of $2.4 million, driven by a significant increase in CyPath Lung test orders and expanded laboratory volumes.

BioAffinity Technologies reports a substantial increase in revenue for 2023, reaching $2.5 million, primarily due to the acquisition of Precision Pathology Laboratory Services and increased sales of their CyPath Lung test.

BioAffinity Technologies has issued 1.6 million shares of common stock and warrants, leading to an adjustment in the exercise price of its existing IPO warrants.

bioAffinity Technologies has successfully raised $2.5 million through a registered direct offering of common stock and a concurrent private placement of warrants.

bioAffinity Technologies announced a 375% increase in CyPath Lung test orders over the past three months, driven by physician interest and a new reimbursement code.

BioAffinity Technologies has adopted a new management incentive bonus plan and approved cash and stock bonuses for several executives.